# Francesco De Rubertis

> Francesco De Rubertis is a Series A investor at Critical Pressure backing Biotechnology. See 21 investments, check sizes, portfolio and contact details…

- Type: Angel Investor
- Fund: Critical Pressure
- Location: Geneva, Switzerland
- Total investments: 21
- Last investment: Dec 2025
- Lead investor: 38%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/in/francesco-de-rubertis-85b214
- X (Twitter): http://twitter.com/fderubertis
- Website: https://x.com/fderubertis

Francesco De Rubertis is a Series A investor at Critical Pressure in Geneva focused on Biotechnology and Pharmaceutical. Francesco De Rubertis is the co-founder and Partner at Medicxi. He is the Board of Director at Ottimo Pharma. He attended the University of Geneva.

## Contacts

5 contacts available for Francesco De Rubertis: work email, personal email, work phone, personal phone and socials. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-email/francesco-de-rubertis?utm_source=investor_profile

## Round sizes

| Stage | Round size |
| --- | --- |
| Seed | $1.2M–$100M |
| Series A | $11M–$140M |
| Series B | $13M–$132M |

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 9 | 43% |
| Pharmaceutical | 5 | 24% |
| Health Care | 4 | 19% |
| Medical | 3 | 14% |
| Therapeutics | 3 | 14% |

13 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series A | 6 | 29% |
| Series B | 5 | 24% |
| Seed | 4 | 19% |
| Series C | 2 | 10% |
| Pre-Seed | 1 | 5% |

7 stages tracked in total.

### Country

| Country | Investments | Share |
| --- | --- | --- |
| United States | 5 | 24% |
| China | 1 | 5% |
| Spain | 1 | 5% |
| Ireland | 1 | 5% |
| Switzerland | 1 | 5% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| D3 Bio | D3 Bio is a globally focused biotechnology company focusing on developing and registration of innovative medicines in oncology and immunology. At D3 Bio, our new medicine development approach is fundamentally differentiated. We do not just only start with science in the lab. First, we pinpoint the greatest unmet patient and market needs – whereexisting standard-of-care approaches yield unsatisfactory clinical outcomes. Then we take those insights into the lab to guide the identification of fit for purpose science and technology and define our drug development path. | $108M | Series B | Dec 09, 2025 |  |
| Ottimo Pharma | Ottimo Pharma is a private biotechnology company dedicated to enhancing cancer treatment outcomes and minimizing the overall healthcare burden. | $140M | Series A | Dec 19, 2024 |  |
| Ottimo Pharma | Ottimo Pharma is a private biotechnology company dedicated to enhancing cancer treatment outcomes and minimizing the overall healthcare burden. |  | Seed | Oct 28, 2024 |  |
| D3 Bio | D3 Bio is a globally focused biotechnology company focusing on developing and registration of innovative medicines in oncology and immunology. At D3 Bio, our new medicine development approach is fundamentally differentiated. We do not just only start with science in the lab. First, we pinpoint the greatest unmet patient and market needs – whereexisting standard-of-care approaches yield unsatisfactory clinical outcomes. Then we take those insights into the lab to guide the identification of fit for purpose science and technology and define our drug development path. | $62M | Series A | Apr 08, 2024 |  |
| Alys Pharmaceuticals | Alys Pharmaceuticals engages in immuno-dermatology services. The company is reshaping the treatment landscape through advanced scientific innovations and a strong research and development-focused multi-platform pipeline. Alys emerged as a result of the strategic aggregation of 6 asset-centric companies backed by Medicxi. | $100M | Seed | Feb 12, 2024 |  |
| Aldena Therapeutics | Aldena Therapeutics is a private biotech startup that invented siRNA-based treatments for dermatological conditions. | $30M | Series A | Mar 16, 2023 |  |
| Velada | Velada is an app that helps users find the ideal restaurant for any occasion by utilizing data to provide personalized recommendations. Tjey also have a proprietary algorithm that uses data from its users' preferences and app behavior to make personalized recommendations, making Velada the first smart restaurant guide. However, without an appor resource that provides a dedicated local guide, travelers frequently find themselves in tourist traps when it comes to their culinary experience. | $1.2M | Seed | Oct 05, 2022 |  |
| Velada | Velada is an app that helps users find the ideal restaurant for any occasion by utilizing data to provide personalized recommendations. Tjey also have a proprietary algorithm that uses data from its users' preferences and app behavior to make personalized recommendations, making Velada the first smart restaurant guide. However, without an appor resource that provides a dedicated local guide, travelers frequently find themselves in tourist traps when it comes to their culinary experience. | $1.1M | Pre-Seed | Oct 05, 2022 |  |
| Rivus Pharmaceuticals | Rivus Pharmaceuticals operates as a biopharmaceutical company dedicated to improving cardio-metabolic health. Rivus Pharmaceuticals is dedicated to improving cardio-metabolic health by developing controlled metabolic accelerators (CMAs) that address the underlying metabolic risk factors for cardiovascular mortality and morbidity. | $132M | Series B | Sep 22, 2022 |  |
| Rivus Pharmaceuticals | Rivus Pharmaceuticals operates as a biopharmaceutical company dedicated to improving cardio-metabolic health. Rivus Pharmaceuticals is dedicated to improving cardio-metabolic health by developing controlled metabolic accelerators (CMAs) that address the underlying metabolic risk factors for cardiovascular mortality and morbidity. | $35M | Series A | Jul 20, 2021 |  |

10 of 21 investments shown.

## Co-investors
- [Advent Venture Partners](https://shizune.co/investors/profile/advent-venture-partners) — VC Fund, 4 deals together
- [Aisling Capital](https://shizune.co/investors/profile/aisling-capital) — VC Fund, 3 deals together
- [Mohr Davidow Ventures](https://shizune.co/investors/profile/mohr-davidow-ventures) — VC Fund, 3 deals together
- [New Leaf Venture Partners](https://shizune.co/investors/profile/new-leaf-venture-partners) — VC Fund, 3 deals together
- [Longitude Capital](https://shizune.co/investors/profile/longitude-capital) — VC Fund, 2 deals together
- [Matrix Partners China](https://shizune.co/investors/profile/matrix-partners-china) — VC Fund, 2 deals together

## About Critical Pressure

VC Fund · Cambridge, United Kingdom

Critical Pressure is a provider of drugs designed to treat to treat vascular dysfunction and shock. The company's technology has the potential to change clinical practice without the potentially harmful effects of excess fluid administration and toxicities associated with the currently available catecholamine-based vasoactive agents, providingthe possibility of supportive therapy during the critical period of haemodynamic compromise.

5 contacts available at Critical Pressure.

| Name | Title | Profile |
| --- | --- | --- |
| Bob Schroff | COO | — |
| David Grainger | CEO | — |
| Francesco De Rubertis | Director | https://shizune.co/investors/profile/francesco-de-rubertis |
| James M. Leiper | CSO | — |
| Simon Lambden | CMO | — |

## Similar investors

### Similar industry
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [FJ Labs](https://shizune.co/investors/profile/fj-labs) — VC Fund
- [SOSV](https://shizune.co/investors/profile/sosv) — VC Fund

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund

### Similar country
- [ENISA](https://shizune.co/investors/profile/enisa-2) — VC Fund
- [Inveready](https://shizune.co/investors/profile/inveready-technology-investment-group) — VC Fund
- [Angels Capital](https://shizune.co/investors/profile/angels-capital) — VC Fund

## Featured in investor lists
- [Restaurants Investors in Spain](https://shizune.co/investors/restaurants-investors-spain)
- [Restaurants Angel Investors in Spain](https://shizune.co/investors/restaurants-angel-investors-spain)
- [Mobile Angel Investors in Spain](https://shizune.co/investors/mobile-angel-investors-spain)
- [Gaming Angel Investors in Spain](https://shizune.co/investors/gaming-angel-investors-spain)
- [Restaurants Angel Investors in Europe](https://shizune.co/investors/restaurants-angel-investors-europe)
- [Mobile Apps Angel Investors in Spain](https://shizune.co/investors/mobile-apps-angel-investors-spain)

## FAQ

### What does Francesco De Rubertis invest in?

Francesco De Rubertis invests primarily in Biotechnology, Pharmaceutical and Health Care startups, most often at Series A and Series B stage. Most of the 21 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### What is Francesco De Rubertis's check size?

Francesco De Rubertis typically joins rounds of $1.2M–$100M at Seed, $11M–$140M at Series A and $13M–$132M at Series B. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Francesco De Rubertis participates in.

### How do I contact Francesco De Rubertis?

Public channels for Francesco De Rubertis include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### When did Francesco De Rubertis last invest?

The most recent investment recorded for Francesco De Rubertis closed in Dec 2025. Shizune tracks 21 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co